Breaking News: Promising Phase II Results
Dr. Rekha Bansal, Founder and CEO
Rekha Bansal, PhD, is the founder and CEO of NovelMed Therapeutics, a pioneering biotechnology company focused on developing innovative therapies targeting the complement Alternative Pathway. With over 20 years of experience in the field of complement biology, Dr. Bansal has made significant contributions to the understanding of the Alternative Pathway and its role in various rare and complement-mediated diseases. She has led the development of NovelMed's portfolio of Alternative Pathway blockers, including two lead candidates, NM8074 and NM5072, which have demonstrated promising results in clinical trials. Dr. Bansal's vision and leadership have positioned NovelMed as a leader in the field of complement therapeutics, dedicated to accelerating treatments for rare diseases.
- Pioneer in the Field of Complement Biology
- Thought Leader in Complement Alternative Pathway Blockers
- More than 80 Issued NovelMed Patents
NovelMed is a clinical stage biotechnology company developing novel biologics for orphan and non-orphan diseases with a specific focus on blocking certain parts of the immune system involved in the disease process. With our unique portfolio of neutralizing monoclonal antibodies, NovelMed is targeting chronic diseases with large market potential and unmet medical need.
We are continuously inventing and developing novel complement-based therapies for rare diseases. Over the last decade, we have generated pre-clinical data and accumulated significant intellectual property to cover the discovery and development of our humanized antibody platform. As a result, we have created an exciting pipeline of therapeutic candidates.
Our portfolio of therapeutic antibodies targets chronic rare diseases of our time, and they have demonstrated a better safety and efficacy profile than two currently marketed drugs.
NovelMed utilizes an innovative R&D strategy, which enables us to block certain parts of the immune system involved in the development and progression of rare diseases. Our portfolio of antibodies is filtered through a unique research pattern to identify best-fit candidates based on affinity, function, and production for further development.
We have achieved remarkable clinical success in advancing multiple antibodies that have a superior mechanism of action compared to those currently under development at other pharmaceutical companies. Our preclinical and clinical studies provide compelling evidence that these antibodies are likely to have a higher level of selectivity and efficacy than competing antibody therapies. Moreover, our antibodies have the potential to be safer due to selectivity for the alternative complement pathway.
